Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, Durand M, Rieux V, Diallo A, Lacabaratz C, Cardinaud S, Zurawski S, Zurawski G, Tomaras GD, Ding S, Centlivre M, Thiebaut R, Pantaleo G, Lelièvre JD, Richert L; ANRS VRI06 Study Group. Levy Y, et al. Among authors: wiedemann a. EClinicalMedicine. 2024 Oct 2;77:102845. doi: 10.1016/j.eclinm.2024.102845. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39649135 Free PMC article.
HIV-1 T cell epitopes targeted to Rhesus macaque CD40 and DCIR: A comparative study of prototype dendritic cell targeting therapeutic vaccine candidates.
Flamar AL, Bonnabau H, Zurawski S, Lacabaratz C, Montes M, Richert L, Wiedemann A, Galmin L, Weiss D, Cristillo A, Hudacik L, Salazar A, Peltekian C, Thiebaut R, Zurawski G, Levy Y. Flamar AL, et al. Among authors: wiedemann a. PLoS One. 2018 Nov 30;13(11):e0207794. doi: 10.1371/journal.pone.0207794. eCollection 2018. PLoS One. 2018. PMID: 30500852 Free PMC article.
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial.
Lévy Y, Lacabaratz C, Ellefsen-Lavoie K, Stöhr W, Lelièvre JD, Bart PA, Launay O, Weber J, Salzberger B, Wiedemann A, Surenaud M, Koelle DM, Wolf H, Wagner R, Rieux V, Montefiori DC, Yates NL, Tomaras GD, Gottardo R, Mayer B, Ding S, Thiébaut R, McCormack S, Chêne G, Pantaleo G. Lévy Y, et al. Among authors: wiedemann a. PLoS Pathog. 2020 Jun 26;16(6):e1008522. doi: 10.1371/journal.ppat.1008522. eCollection 2020 Jun. PLoS Pathog. 2020. PMID: 32589686 Free PMC article. Clinical Trial.
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.
Richert L, Lelièvre JD, Lacabaratz C, Hardel L, Hocini H, Wiedemann A, Lucht F, Poizot-Martin I, Bauduin C, Diallo A, Rieux V, Rouch E, Surenaud M, Lefebvre C, Foucat E, Tisserand P, Guillaumat L, Durand M, Hejblum B, Launay O, Thiébaut R, Lévy Y; ANRS VRI01 Study Group. Richert L, et al. Among authors: wiedemann a. J Immunol. 2022 Jun 15;208(12):2663-2674. doi: 10.4049/jimmunol.2101076. Epub 2022 May 25. J Immunol. 2022. PMID: 35613727 Clinical Trial.
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine.
Coléon S, Wiedemann A, Surénaud M, Lacabaratz C, Hue S, Prague M, Cervantes-Gonzalez M, Wang Z, Ellis J, Sansoni A, Pierini C, Bardin Q, Fabregue M, Sharkaoui S, Hoest P, Dupaty L, Picard F, El Hajj M, Centlivre M, Ghosn J; French COVID Cohort Study Group; Thiébaut R, Cardinaud S, Malissen B, Zurawski G, Zarubica A, Zurawski SM, Godot V, Lévy Y. Coléon S, et al. Among authors: wiedemann a. EBioMedicine. 2022 Jun;80:104062. doi: 10.1016/j.ebiom.2022.104062. Epub 2022 May 17. EBioMedicine. 2022. PMID: 35594660 Free PMC article.
[Deficiency of HIV-specific T cell responses: are the Treg guilty?].
Nikolova M, Wiedemann A, Lacabaratz C, Lévy Y. Nikolova M, et al. Among authors: wiedemann a. Med Sci (Paris). 2017 Aug-Sep;33(8-9):723-726. doi: 10.1051/medsci/20173308012. Epub 2017 Sep 18. Med Sci (Paris). 2017. PMID: 28945557 Free article. French. No abstract available.
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Bétard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R; EBOVAC2 EBL2001 study group. Pollard AJ, et al. Among authors: wiedemann a. Lancet Infect Dis. 2021 Apr;21(4):493-506. doi: 10.1016/S1473-3099(20)30476-X. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217361 Clinical Trial.
421 results